Following the announced merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) today, John Colley, Professor of Practice at Warwick Business School, UK, and an expert on large-scale mergers, has made the following comments:
"Botox producer Allergan has been acquired for $160 billion by Pfizer to make it the world's largest pharmaceutical business. This deal follows a pattern in which the pharmaceutical industry has seen acquisitions totalling over $600 billion this year as the industry consolidates.
"Industry valuations increase as industry players become concerned at being left behind in the race for scale. In the instance of Pfizer it is also pursuing greater growth as its own established products are losing patent protection at a greater rate than it can produce innovative products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze